SAN DIEGO & CALGARY--(BUSINESS WIRE)--Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) announced today that it has completed the planned exploratory efficacy analysis of the data from the Phase I, 7 day RVX-208 treatment subjects. Analysis from two independent and external laboratories of blinded serum samples showed consistent improvements of key biomarkers for the RCT (reverse cholesterol transport) pathway.
